Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (2)

Trial Status

Recruiting2
Terminated1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06995677Phase 2Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06915753Phase 1Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT02706691Phase 2TerminatedPrimary

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Showing all 3 trials

Research Network

Activity Timeline